Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 24576679)

1.

Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia.

Asevedo E, Rizzo LB, Gadelha A, Mansur RB, Ota VK, Berberian AA, Scarpato BS, Teixeira AL, Bressan RA, Brietzke E.

Physiol Behav. 2014 Apr 22;129:194-8. doi: 10.1016/j.physbeh.2014.02.032. Epub 2014 Feb 25.

2.

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia.

Asevedo E, Gadelha A, Noto C, Mansur RB, Zugman A, Belangero SI, Berberian AA, Scarpato BS, Leclerc E, Teixeira AL, Gama CS, Bressan RA, Brietzke E.

J Psychiatr Res. 2013 Oct;47(10):1376-82. doi: 10.1016/j.jpsychires.2013.05.032. Epub 2013 Jun 25.

PMID:
23806580
3.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
4.

[Neurocognitive function in clinically stable patients with schizophrenia or bipolar disorder and normal controls].

Konstantakopoulos G, Ioannidi N, Patrikelis P, Soumani A, Oulis P, Sakkas D, Papadimitriou GN, Ploumpidis D.

Psychiatriki. 2011 Jul-Sep;22(3):195-206. Greek, Modern.

PMID:
21971195
5.

Community dysfunction in schizophrenia: rate-limiting factors.

Bozikas VP, Kosmidis MH, Kafantari A, Gamvrula K, Vasiliadou E, Petrikis P, Fokas K, Karavatos A.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):463-70. Epub 2006 Jan 25.

PMID:
16442195
6.

[Influence of attention on an auditory-verbal learning test in schizophrenic patients].

Huguelet P, Nicastro R, Zanello A.

Encephale. 2002 Jul-Aug;28(4):291-7. French.

PMID:
12232538
7.

Schizophrenia patients with and without post-traumatic stress disorder (PTSD) have different mood symptom levels but same cognitive functioning.

Peleikis DE, Varga M, Sundet K, Lorentzen S, Agartz I, Andreassen OA.

Acta Psychiatr Scand. 2013 Jun;127(6):455-63. doi: 10.1111/acps.12041. Epub 2012 Nov 26.

PMID:
23176609
8.

Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients.

Bellino S, Rocca P, Patria L, Marchiaro L, Rasetti R, Di Lorenzo R, Paradiso E, Bogetto F.

J Clin Psychiatry. 2004 Jul;65(7):908-14.

PMID:
15291678
9.

Clinical correlates associated with cognitive dysfunction in people with schizophrenia.

Tanaka T, Tomotake M, Ueoka Y, Kaneda Y, Taniguchi K, Nakataki M, Numata S, Tayoshi S, Yamauchi K, Sumitani S, Ohmori T, Ueno S, Ohmori T.

Psychiatry Clin Neurosci. 2012 Oct;66(6):491-8. doi: 10.1111/j.1440-1819.2012.02390.x.

PMID:
23066766
10.

Decreased interleukin-10 serum levels in first-episode drug-naïve schizophrenia: relationship to psychopathology.

Xiu MH, Yang GG, Tan YL, Chen da C, Tan SP, Wang ZR, Yang FD, Okusaga O, Soares JC, Zhang XY.

Schizophr Res. 2014 Jun;156(1):9-14. doi: 10.1016/j.schres.2014.03.024. Epub 2014 Apr 22.

PMID:
24766914
11.

Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia.

Takahashi S, Ukai S, Kose A, Hashimoto T, Iwatani J, Okumura M, Tsuji T, Shinosaki K.

Schizophr Res. 2013 May;146(1-3):238-43. doi: 10.1016/j.schres.2013.02.033. Epub 2013 Mar 22.

PMID:
23523695
12.

Association of decreased prefrontal hemodynamic response during a verbal fluency task with EGR3 gene polymorphism in patients with schizophrenia and in healthy individuals.

Nishimura Y, Takizawa R, Koike S, Kinoshita A, Satomura Y, Kawasaki S, Yamasue H, Tochigi M, Kakiuchi C, Sasaki T, Iwayama Y, Yamada K, Yoshikawa T, Kasai K.

Neuroimage. 2014 Jan 15;85 Pt 1:527-34. doi: 10.1016/j.neuroimage.2013.08.021. Epub 2013 Aug 17.

PMID:
23962955
13.

Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale.

Boyer L, Richieri R, Guedj E, Faget-Agius C, Loundou A, Llorca PM, Auquier P, Lançon C.

Compr Psychiatry. 2013 Oct;54(7):1016-22. doi: 10.1016/j.comppsych.2013.04.008. Epub 2013 May 31.

PMID:
23731897
14.
15.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
16.

Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia.

Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P, Caspari D.

Eur Arch Psychiatry Clin Neurosci. 2007 Jun;257(4):203-10. Epub 2006 Nov 25.

PMID:
17131214
17.

Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia.

Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI.

Schizophr Res. 1997 May 3;25(1):1-10.

PMID:
9176922
18.

Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology.

Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC.

Schizophr Res. 2002 Oct 1;57(2-3):247-58. Erratum in: Schizophr Res. 2003 Mar 1;60(1):101..

PMID:
12223256
19.

Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz).

Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A, Yagi G, Watanabe K, Kashima H.

Schizophr Res. 2008 Dec;106(2-3):328-36. doi: 10.1016/j.schres.2008.08.013. Epub 2008 Sep 19.

PMID:
18804960
20.

Estrogen, cognitive function and negative symptoms in female schizophrenia.

Ko YH, Joe SH, Cho W, Park JH, Lee JJ, Jung IK, Kim L, Kim SH.

Neuropsychobiology. 2006;53(4):169-75. Epub 2006 Jun 6.

PMID:
16763376
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk